-
Start Preamble
Start Printed Page 17942
AGENCY:
Food and Drug Administration, Department of Health and Human Services (HHS).
ACTION:
Final rule; technical amendments.
SUMMARY:
The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during October, November, and December 2021. FDA is informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to improve the accuracy of the regulations.
DATES:
This rule is effective March 29, 2022.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, George.Haibel@fda.hhs.gov.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
I. Approvals
FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during October, November, and December 2021, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the office of the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500. Persons with access to the internet may obtain these documents at the CVM FOIA Electronic Reading Room: https://www.fda.gov/about-fda/center-veterinary-medicine/cvm-foia-electronic-reading-room. Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: https://www.fda.gov/animal-veterinary/products/approved-animal-drug-products-green-book.
FDA has verified the website addresses as of the date this document publishes in the Federal Register , but websites are subject to change over time.
Table 1—Original and Supplemental NADAs and ANADAs Approved During October, November, and December 2021
Approval date File No. Sponsor Product name Species Effect of the action Public documents October 1, 2021 200-691 Virbac AH, Inc., P.O. Box 162059, Fort Worth, TX 76161 RAC 45 CATTLE (ractopamine hydrochloride Type A medicated article) Cattle Original approval as a generic copy of NADA 141-221 FOI Summary. October 20, 2021 200-604 Dechra Veterinary Products LLC, 7015 College Blvd., Suite 525, Overland Park, KS 66211 Amoxicillin and Clavulanate Potassium for Oral Suspension Dogs and cats Original approval as a generic copy of NADA 055-101 FOI Summary. October 28, 2021 200-588 Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215 Florfenicol Injection (florfenicol) Injectable Solution Cattle Original approval as a generic copy of NADA 141-063 FOI Summary. October 29, 2021 200-628 Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215 Enrofloxacin 100 (enrofloxacin) Injectable Solution Cattle and swine Original approval as a generic copy of NADA 141-068 FOI Summary. October 29, 2021 141-348 Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 SYNOVEX ONE Grower (trenbolone acetate and estradiol benzoate extended-release implants) Cattle Supplemental approval adding cattle fed in confinement for slaughter FOI Summary. November 1, 2021 200-711 Ceva Sante Animale, 10 Avenue de la Ballastière, 33500 Libourne, France TULAVEN 100 (tulathromycin injection) Injectable Solution Cattle and swine Original approval as a generic copy of NADA 141-244 FOI Summary. November 3, 2021 200-712 Ceva Sante Animale, 10 Avenue de la Ballastière, 33500 Libourne, France TULAVEN 25 (tulathromycin injection) Injectable Solution Cattle and swine Original approval as a generic copy of NADA 141-349 FOI Summary. November 3, 2021 141-508 Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140 EXPERIOR (lubabegron) Type A medicated article Cattle Supplemental approval adding tolerances for residues in edible tissues of cattle FOI Summary. November 12, 2021 200-668 Virbac AH, Inc., P.O. Box 162059, Fort Worth, TX 76161 TULISSIN 25 (tulathromycin injection) Injectable Solution Cattle and swine Original approval as a generic copy of NADA 141-349 FOI Summary. November 15, 2021 200-253 Bimeda Animal Health Ltd., 1B The Herbert Building, The Park, Carrickmines, Dublin 18, Ireland PROSTAMATE (dinoprost tromethamine injection) Injectable Solution Cattle Supplemental approval for use with gonadorelin or with progesterone intravaginal inserts FOI Summary. November 15, 2021 200-669 Virbac AH, Inc., P.O. Box 162059, Fort Worth, TX 76161 TULISSIN 100 (tulathromycin injection) Injectable Solution Cattle and swine Original approval as a generic copy of NADA 141-244 FOI Summary. Start Printed Page 17943 November 22, 2021 200-695 Virbac AH, Inc., P.O. Box 162059, Fort Worth, TX 76161 TIA 12.5% (tiamulin hydrogen fumarate) Liquid Concentrate Swine Original approval as a generic copy of NADA 140-916 FOI Summary. November 24, 2021 200-714 Aurora Pharmaceutical, Inc, 1196 Highway 3 South, Northfield, MN 55057-3009 BARRIER for Cats (imidacloprid and moxidectin) Topical Solution Cats Original approval as a generic copy of NADA 141-254 FOI Summary. December 10, 2021 200-705 Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140 ZOASHIELD (zoalene) Type A medicated article and BMD (bacitracin methylenedisalicylate) Type A medicated article Chickens and turkeys Original approval as a generic copy of NADA 141-085 FOI Summary. December 21, 2021 141-552 Jaguar Animal Health, 200 Pine St., suite 600, San Francisco, CA 94104 CANALEVIA-CA1 (crofelemer delayed-release tablets) Dogs Conditional approval for treatment of chemotherapy-induced diarrhea FOI Summary. December 23, 2021 141-521 Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 SIMPARICA TRIO (sarolaner, moxidectin, and pyrantel chewable tablets) Chewable Tablet Dogs Supplemental approval for the prevention of Borrelia burgdorferi infection as a direct result of killing Ixodes scapularis vector ticks and for the treatment and control of L4 and immature adult Ancylostoma caninum FOI Summary. II. Change of Sponsor
Elanco US Inc., 2500 Innovation Way, Greenfield, IN 46140 has informed FDA that it has transferred ownership of, and all rights and interest in, the NADAs and ANADAs listed below to Dechra, Ltd., Snaygill Industrial Estate, Keighley Rd., Skipton, North Yorkshire, BD23 2RW, United Kingdom:
File No. Product name 047-955 ROMPUN (xylazine hydrochloride) Injectable (20 mg). 047-956 ROMPUN (xylazine hydrochloride) Injectable (100 mg). 200-322 Butorphanol Tartrate Injection. 200-408 Butorphanol Tartrate Injection. Thorn Bioscience LLC, 1044 East Chestnut St., Louisville, KY 40204 has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 141-319 for SUCROMATE Equine (deslorelin acetate injection) to Dechra, Ltd., Snaygill Industrial Estate, Keighley Rd., Skipton, North Yorkshire, BD23 2RW, United Kingdom.
As provided in the regulatory text, the animal drug regulations are amended to reflect these changes of sponsorship.
III. Technical Amendments
FDA is making the following amendments to improve the accuracy of the animal drug regulations:
- 21 CFR 510.600 is amended to add Jaguar Animal Health and remove Thorn Bioscience LLC from the list of sponsors of approved applications.
- 21 CFR 520.88h is amended to correct indications for use in cats of an oral suspension containing amoxicillin and clavulanate.
- 21 CFR 520.2455 is amended to correct a spelling error in the limitations for use of tiamulin in drinking water of swine.
- 21 CFR 522.230 is amended to add the caution that buprenorphine injectable solution is a Schedule III opioid under the Controlled Substances Act.
- 21 CFR 522.690 is amended to reflect revised indications for use of dinoprost tromethamine injectable solution in mares.
- 21 CFR 522.1940 is amended to reflect the approved classes of cattle and limitations for use of progesterone and estradiol benzoate ear implants.
- 21 CFR 522.2343 is amended to reflect the approved classes of cattle and limitations for use of testosterone propionate and estradiol benzoate ear implants.
- 21 CFR 556.240 is amended to reflect the use of revised food consumption values in establishing permitted concentrations of residues of estradiol and related esters in edible tissues of cattle. The basis for this action is explained in the FOI Summary for supplemental NADA 141-348, approved October 29, 2021. The section is also amended to reflect a cross reference for testosterone propionate and estradiol benzoate implants, recently redesignated as 21 CFR 522.2343.
- 21 CFR 558.254 is amended to reflect the approved conditions of use for famphur in feed.
- 21 CFR 558.355 is amended to reflect use of medicated feeds containing monensin alone or in combination with bacitracin methylenedisalicylate in revised classes of chickens.
- 21 CFR 558.555 is amended to correct a spelling error in the permitted combination use of semduramicin in medicated feed.
- 21 CFR 558.633 is amended to revise expiration dates for use of pelleted or crumbled tylvalosin medicated swine feeds.
- 21 CFR 558.680 is amended to reflect the correct sponsor of an application for use of Type C medicated turkey feeds containing zoalene.
IV. Legal Authority
This final rule is issued under section 512(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C.360b(i)), which requires Federal Register publication of “notice[s] . . . effective as a regulation,” of the conditions of use of approved new animal drugs. This rule sets forth Start Printed Page 17944 technical amendments to the regulations to codify recent actions on approved new animal drug applications and corrections to improve the accuracy of the regulations, and as such does not impose any burden on regulated entities.
Although denominated a rule pursuant to the FD&C Act, this document does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a “rule of particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808. Likewise, this is not a rule subject to Executive Order 12866, which defines a rule as “an agency statement of general applicability and future effect, which the agency intends to have the force and effect of law, that is designed to implement, interpret, or prescribe law or policy or to describe the procedure or practice requirements of an agency.”
Start List of SubjectsList of Subjects
21 CFR Part 510
- Administrative practice and procedure
- Animal drugs
- Labeling
- Reporting and recordkeeping requirements
21 CFR Part 516
- Administrative practice and procedure
- Animal drugs
- Confidential business information
- Reporting and recordkeeping requirements
21 CFR Parts 520, 522, 524, and 529
- Animal drugs
21 CFR Part 556
- Animal drugs
- Dairy products
- Foods
- Meat and meat products
21 CFR Part 558
- Animal drugs
- Animal feeds
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 510, 516, 520, 522, 524, 529, 556, and 558 are amended as follows:
Start PartPART 510—NEW ANIMAL DRUGS
End Part Start Amendment Part1. The authority citation for part 510 continues to read as follows:
End Amendment Part Start Amendment Part2. In § 510.600:
End Amendment Part Start Amendment Parta. In the table in paragraph (c)(1), add in alphabetical order an entry for “Jaguar Animal Health” and remove the entry for “Thorn Bioscience LLC”; and
End Amendment Part Start Amendment Partb. In the table in paragraph (c)(2), remove the entry for “051330” and add in numerical order an entry for “086149”.
End Amendment PartThe additions read as follows:
Names, addresses, and drug labeler codes of sponsors of approved applications.* * * * *(c) * * *
(1) * * *
Firm name and address Drug labeler code * * * * * * * Jaguar Animal Health, 200 Pine St., Suite 600, San Francisco, CA 94104 086149 * * * * * * * (2) * * *
Drug labeler code Firm name and address * * * * * * * 086149 Jaguar Animal Health, 200 Pine St., Suite 600, San Francisco, CA 94104. * * * * * * * PART 516—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES
End Part Start Amendment Part3. The authority citation for part 516 continues to read as follows:
End Amendment Part Start Amendment Part4. Add § 516.498 to subpart C to read as follows:
End Amendment PartCrofelemer.(a) Specifications. Each delayed-release tablet contains 125 milligrams (mg) crofelemer.
(b) Sponsor. See No. 086149 in § 510.600(c) of this chapter.
(c) Conditions of use —(1) Amount. Administer 1 tablet orally twice daily for 3 days for dogs weighing ≤140 pounds. Administer 2 tablets orally twice daily for 3 days for dogs weighing >140 pounds.
(2) Indications for use. For the treatment of chemotherapy-induced diarrhea in dogs.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling.
PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part5. The authority citation for part 520 continues to read as follows:
End Amendment Part Start Amendment Part6. Revise § 520.88h to read as follows:
End Amendment PartAmoxicillin trihydrate and clavulanate potassium for oral suspension.(a) Specifications. When constituted, each milliliter (mL) of suspension contains amoxicillin trihydrate equivalent to 50 milligrams (mg) amoxicillin and clavulanate potassium equivalent to 12.5 mg clavulanic acid.
(b) Sponsors. See Nos. 017033, 054771, and 069043 in § 510.600(c) of this chapter.
(c) Conditions of use —(1) Dogs —(i) Amount. 6.25 mg/lb (1 mL/10 lb of body weight) twice a day. Skin and soft tissue infections such as abscesses, cellulitis, wounds, superficial/juvenile pyoderma, and periodontal infections should be treated for 5 to 7 days or for 48 hours after all signs have subsided. If no Start Printed Page 17945 response is seen after 5 days of treatment, therapy should be discontinued and the case reevaluated. Deep pyoderma may require treatment for 21 days; the maximum duration of treatment should not exceed 30 days.
(ii) Indications for use. Treatment of skin and soft tissue infections such as wounds, abscesses, cellulitis, superficial/juvenile and deep pyoderma due to susceptible strains of the following organisms: Beta-lactamase-producing Staphylococcus aureus, non-beta-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., and Escherichia coli. Treatment of periodontal infections due to susceptible strains of both aerobic and anaerobic bacteria.
(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) Cats —(i) Amount. 62.5 mg (1 mL) twice daily. Skin and soft tissue infections such as abscesses and cellulitis/dermatitis should be treated for 5 to 7 days or 48 hours after all symptoms have subsided, not to exceed 30 days. If no response is seen after 3 days of treatment, therapy should be discontinued and the case reevaluated. Urinary tract infections may require treatment for 10 to 14 days or longer. The maximum duration of treatment should not exceed 30 days.
(ii) Indications for use. Treatment of skin and soft tissue infections, such as wounds, abscesses, and cellulitis/dermatitis due to susceptible strains of the following organisms: Beta-lactamase-producing Staphylococcus aureus, non-beta-lactamase-producing Staphylococcus aureus, Staphylococcus spp., Streptococcus spp., Escherichia coli, Pasteurella multocida, and Pasteurella spp. Urinary tract infections (cystitis) due to susceptible strains of E. coli.
(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
7. In § 520.2090, revise paragraph (c)(2) to read as follows:
End Amendment PartSarolaner, moxidectin, and pyrantel.* * * * *(c) * * *
(2) Indications for use. For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina ) and hookworm (L4, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala ) infections. Kills adult fleas ( Ctenocephalides felis ) and is indicated for the treatment and prevention of flea infestations, and the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick) for 1 month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater. For the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.
* * * * *8. In § 520.2455:
End Amendment Part Start Amendment Parta. Revise paragraphs (b)(1) through (4); and
End Amendment Part Start Amendment Partb. In paragraph (d)(2), remove “semduramycin” and in its place add “semduramicin.”
End Amendment PartThe revisions read as follows:
Tiamulin.* * * * *(b) * * *
(1) No. 058198 for products described in paragraph (a) of this section.
(2) No. 066104 for product described in paragraph (a)(1) of this section.
(3) Nos. 016592, 051311, and 061133 for product described in paragraph (a)(2) of this section.
(4) No. 054771 for product described in paragraph (a)(3) of this section.
* * * * *PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part9. The authority citation for part 522 continues to read as follows:
End Amendment Part Start Amendment Part10. In § 522.246, revise paragraphs (b)(2) and (3) to read as follows:
End Amendment PartButorphanol.* * * * *(b) * * *
(2) No. 043264 for use of the product described in paragraph (a)(2) of this section as in paragraph (d)(2) of this section.
(3) Nos. 000061, 043264, and 059399 for use of the product described in paragraph (a)(3) of this section as in paragraph (d)(3) of this section.
* * * * *[Amended]11. In § 522.533, in paragraph (b)(2), remove “051330” and in its place add “043264”.
End Amendment Part Start Amendment Part12. In § 522.690:
End Amendment Part Start Amendment Parta. Revise paragraphs (a) and (b);
End Amendment Part Start Amendment Partb. Revise paragraph (d)(1) introductory text and paragraph (d)(1)(i);
End Amendment Part Start Amendment Partc. Add paragraph (d)(2) introductory text;
End Amendment Part Start Amendment Partd. Revise paragraph (d)(2)(ii);
End Amendment Part Start Amendment Parte. Add paragraph (d)(3) introductory text;
End Amendment Part Start Amendment Partf. Revise paragraph (d)(3)(ii); and
End Amendment Part Start Amendment Partg. Remove paragraph (d)(4).
End Amendment PartThe revisions and additions read as follows:
Dinoprost.(a) Specifications. Each milliliter (mL) of solution contains dinoprost tromethamine equivalent to:
(1) 5 milligrams (mg) dinoprost; or
(2) 12.5 mg dinoprost.
(b) Sponsors. See sponsors in § 510.600(c) of this chapter as follows:
(1) Nos. 054771 and 061133 for use of product described in paragraph (a)(1) as in paragraph (d) of this section.
(2) No. 054771 for use of product described in paragraph (a)(2) as in paragraph (d)(1) of this section.
* * * * *(d) * * *
(1) Cattle. Administer products described in paragraph (a) of this section as follows:
(i) Amount. 25 mg as an intramuscular injection of the 5 mg/mL product or as an intramuscular or subcutaneous injection of the 12.5 mg/mL product.
* * * * *(2) * * * Administer product described in paragraph (a)(1) of this section as follows:
* * * * *(ii) Indications for use. (A) For controlling the timing of estrus in estrous cycling mares.
(B) For difficult-to-breed mares (clinically anestrous mares that have a corpus luteum).
* * * * *(3) * * * Administer product described in paragraph (a)(1) of this section as follows:
* * * * *(ii) Indications for use. For parturition induction in swine.
13. In § 522.812, revise paragraph (b)(2) to read as follows:
End Amendment PartEnrofloxacin.* * * * *(b) * * *
(2) Nos. 055529, 058005, 058198, and 061133 for use of product described in paragraph (a)(2) of this section as in paragraphs (e)(2) and (3) of this section.
* * * * *[Amended]14. In § 522.955, in paragraph (b)(3), remove “No. 086050” and in its place Start Printed Page 17946 add “Nos. 058005 and 086050”; and in paragraph (d)(1)(ii)(C), remove “No. 000061” and in its place add “Nos. 000061, 058005, and 086050”.
End Amendment Part Start Amendment Part15. In § 522.1077, revise paragraph (d)(1)(iv) to read as follows:
End Amendment PartGonadorelin.* * * * *(d) * * *
(1) * * *
(iv) Dinoprost injection for use as in paragraph (e)(1)(vi) of this section as provided by Nos. 054771 and 061133 in § 510.600(c) of this chapter.
* * * * *16. In § 522.1940, revise the paragraph (c)(1) heading, paragraph (c)(1)(iii), the paragraph (c)(2) heading, and paragraph (c)(2)(iii) to read as follows:
End Amendment PartProgesterone and estradiol benzoate.* * * * *(c) * * *
(1) Suckling beef calves at least 45 days old and up to 400 lb of body weight —* * *
* * * * *(iii) Limitations. For subcutaneous ear implantation, one dose per animal. Do not use in beef calves less than 45 days of age, dairy calves, and veal calves because effectiveness and safety have not been established. Do not use in animals intended for subsequent breeding, or in dairy cows. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
(2) Growing beef steers weighing 400 lb or more —* * *
* * * * *(iii) Limitations. For subcutaneous ear implantation, one dose per animal. Do not use in beef calves less than 45 days of age, dairy calves, and veal calves because effectiveness and safety have not been established. Do not use in animals intended for subsequent breeding, or in dairy cows. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
* * * * *17. In § 522.2343, revise paragraph (c) introductory text and paragraph (c)(3) to read as follows:
End Amendment PartTestosterone propionate and estradiol benzoate.* * * * *(c) Conditions of use. For implantation in growing beef heifers weighing 400 lb or more as follows:
* * * * *(3) Limitations. For subcutaneous ear implantation, one dose per animal. Not for use in dairy or beef replacement heifers. Do not use in beef calves less than 2 months of age, dairy calves, and veal calves because safety and effectiveness have not been established. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
18. In § 522.2478, redesignate paragraph (d)(3) as paragraph (d)(4); add new paragraph (d)(3); and revise newly redesignated paragraph (d)(4) heading and paragraph (d)(4)(i)(C) to read as follows:
End Amendment PartTrenbolone acetate and estradiol benzoate.* * * * *(d) * * *
(3) Growing beef steers and heifers fed in confinement for slaughter. (i) For an implant as described in paragraph (a)(2)(ii) of this section:
(A) Amount. 150 mg trenbolone acetate and 21 mg estradiol benzoate in an extended-release implant.
(B) Indications for use. For increased rate of weight gain for up to 200 days.
(C) Limitations. Implant pellets subcutaneously in ear only. Not approved for repeated implantation (reimplantation) with this or any other cattle ear implant within each separate production phase. Safety and effectiveness following reimplantation have not been evaluated. Do not use in beef calves less than 2 months of age, dairy calves, and veal calves because effectiveness and safety have not been established. Do not use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in dairy cows or in animals intended for subsequent breeding. Use in these cattle may cause drug residues in milk and/or in calves born to these cows.
(ii) [Reserved]
(4) Growing beef steers and heifers on pasture (stocker, feeder, and slaughter). (i) * * *
(C) Limitations. Implant pellets subcutaneously in ear only. Not approved for repeated implantation (reimplantation) with this or any other cattle ear implant within each separate production phase. Safety and effectiveness following reimplantation have not been evaluated. Do not use in beef calves less than 2 months of age, dairy calves, and veal calves because effectiveness and safety have not been established. Do not use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in preruminating calves. Do not use in dairy cows or in animals intended for subsequent breeding. Use in these cattle may cause drug residues in milk and/or in calves born to these cows.
* * * * *19. In 522.2630, revise paragraphs (b)(1) and (2) to read as follows:
End Amendment PartTulathromycin.* * * * *(b) * * *
(1) Nos. 013744, 051311, 054771, 058198, and 061133 for use of product described in paragraph (a)(1) as in paragraphs (d)(1)(i) and (ii), (d)(1)(iii)(A), and (d)(2) of this section.
(2) Nos. 013744, 051311, and 054771 for use of product described in paragraph (a)(2) as in paragraphs (d)(1)(i), (d)(1)(ii)(B), (d)(1)(iii)(B), and (d)(2) of this section.
* * * * *20. In § 522.2662, revise paragraph (b)(3) to read as follows:
End Amendment PartXylazine.* * * * *(b) * * *
(3) Nos. 043264 and 061651 for use of product described in paragraph (a)(1) of this section as in paragraph (d)(1) of this section; and product described in paragraph (a)(2) of this section as in paragraphs (d)(2), (d)(3)(i), (d)(3)(ii)(A), and (d)(3)(iii) of this section.
* * * * *PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part21. The authority citation for part 524 continues to read as follows:
End Amendment Part Start Amendment Part22. In § 524.1146, revise paragraphs (b)(2) and (3) to read as follows:
End Amendment PartImidacloprid and moxidectin.* * * * *(b) * * *
(2) Nos. 051072, 017030, 058198, and 061651 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(2) of this section.
(3) Nos. 051072 and 058198 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(3) of this section.
* * * * *PART 529—CERTAIN OTHER DOSAGE FORM NEW ANIMAL DRUGS
End Part Start Amendment Part23. The authority citation for part 529 continues to read as follows:
End Amendment Part Start Printed Page 17947 Start Amendment Part24. In § 529.1940, revise the last sentence in paragraph (e)(1)(iii) to read as follows:
End Amendment PartProgesterone intravaginal inserts.* * * * *(e) * * *
(1) * * *
(iii) * * * Dinoprost injection for use as in paragraphs (e)(1)(ii)(A) and (B) of this section as in § 522.690 of this chapter, provided by Nos. 054771 and 061133 in § 510.600(c) of this chapter.
* * * * *PART 556—TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD
End Part Start Amendment Part25. The authority citation for part 556 continues to read as follows:
End Amendment Part Start Amendment Part26. In 556.240, revise paragraphs (b)(1) and (c) to read as follows:
End Amendment PartEstradiol and related esters.* * * * *(b) * * *
(1) Cattle. (i) Muscle: 0.2 ppb.
(ii) Liver: 0.6 ppb.
(iii) Kidney: 1.2 ppb.
(iv) Fat: 1.2 ppb.
* * * * *(c) Related conditions of use. See §§ 522.840, 522.850, 522.1940, 522.2343, 522.2477, and 522.2478 of this chapter.
27. In § 556.370, revise paragraph (b) to read as follows:
End Amendment PartLubabegron.* * * * *(b) Tolerances. The tolerances for lubabegron (marker residue) are:
(1) Cattle. (i) Liver (target tissue): 10 ppb.
(ii) Muscle: 3 ppb.
(iii) Kidney: 20 ppb.
(2) [Reserved]
* * * * *PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
End Part Start Amendment Part28. The authority citation for part 558 continues to read as follows:
End Amendment Part Start Amendment Part29. In § 558.254, revise paragraph (e) to read as follows:
End Amendment PartFamphur.* * * * *(e) Conditions of use. It is used in cattle feed as follows:
Famphur amount Indications for use Limitations Sponsor (1) To provide 1.1 milligrams per pound (mg/lb) body weight per day Beef cattle and nonlactating dairy cattle: For control of grubs and as an aid in control of sucking lice Feed for 30 days. Withdraw from dry dairy cows and heifers 21 days prior to freshening. Withdraw 4 days prior to slaughter 000061 (2) To provide 2.3 mg/lb body weight per day Beef cattle and nonlactating dairy cattle: For control of grubs Feed for 10 days. Withdraw from dry dairy cows and heifers 21 days prior to freshening. Withdraw 4 days prior to slaughter 000061 30. In § 558.355, revise paragraphs (d)(8)(vi) and (f)(1)(ii), (iv), and (vi) to read as follows:
End Amendment PartMonensin.* * * * *(d) * * *
(8) * * *
(vi) Not for replacement chickens intended to become broiler breeding chickens.
* * * * *(f) * * *
(1) * * *
Monensin in grams/ton Combination in grams/ton Indications for use Limitations Sponsor * * * * * * * (ii) 90 to 110 Layer replacement chickens: As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima Feed continuously as the sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens 058198 * * * * * * * (iv) 90 to 110 Bacitracin methylenedisalicylate, 4 to 50 Layer replacement chickens: As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima, and for increased rate of weight gain and improved feed efficiency Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. Monensin sodium provided by No. 058198, bacitracin methylenedisalicylate provided by No. 054771 in § 510.600(c) of this chapter 054771 * * * * * * * (vi) 90 to 110 Bacitracin methylenedisalicylate, 50 Broiler and layer replacement chickens: As an aid in the prevention of coccidiosis caused by E. necatrix, E. tenella, E. acervulina, E. brunetti, E. mivati, and E. maxima, and for improved feed efficiency, and as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin Feed continuously as sole ration. Do not feed to chickens over 16 weeks of age. Do not feed to laying chickens. Monensin sodium provided by No. 058198, bacitracin methylenedisalicylate provided by No. 054771 in § 510.600(c) of this chapter 054771 * * * * * * * * * * * *31. In § 558.500, revise paragraphs (b) and (e)(2)(i), (iii), and (vi) to read as follows:
End Amendment PartRactopamine.* * * * *(b) Sponsors. See sponsor numbers in § 510.600(c) of this chapter.
(1) No. 058198: Type A medicated articles containing 9 or 45.4 grams per pound (g/lb) ractopamine hydrochloride. Start Printed Page 17948
(2) Nos. 016592, 051311, and 054771: Type A medicated articles containing 45.4 g/lb ractopamine hydrochloride.
* * * * *(e) * * *
(2) * * *
Ractopamine in grams/ton Combination in grams/ton Indications for use Limitations Sponsor (i) 8.2 to 24.6 Cattle fed in confinement for slaughter: For increased rate of weight gain and improved feed efficiency during the last 28 to 42 days on feed Feed continuously as sole ration during the last 28 to 42 days on feed. Not for animals intended for breeding 016592 051311 054771 058198 * * * * * * * (iii) 9.8 to 24.6 Cattle fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness during the last 28 to 42 days on feed Feed continuously as sole ration during the last 28 to 42 days on feed. Not for animals intended for breeding 016592 051311 054771 058198 * * * * * * * (vi) Not to exceed 800; to provide 70 to 400 mg/head/day Cattle fed in confinement for slaughter: For increased rate of weight gain and improved feed efficiency during the last 28 to 42 days on feed Top dress ractopamine at a minimum of 1.0 lb/head/day of medicated feed continuously during the last 28 to 42 days on feed. Not for animals intended for breeding. 016592 051311 054771 058198 * * * * * * * * * * * *[Amended]32. In § 558.555, in paragraph (f), remove “Semduramycin” and in its place add “Semduramicin”.
End Amendment Part Start Amendment Part33. In § 558.633, revise paragraph (d)(3) to read as follows:
End Amendment PartTylvalosin.* * * * *(d) * * *
(3) Pelleted Type C medicated feeds must bear an expiration date of 30 days after the date of manufacture. Crumbled Type C medicated feeds must bear an expiration date of 7 days after the date of manufacture.
* * * * *34. In § 558.680, revise paragraphs (d)(1)(iii), (iv), (vii), and (viii) and (d)(2) to read as follows:
End Amendment PartZoalene.* * * * *(d) * * *
(1) * * *
Zoalene in grams/ton Combination in grams/ton Indications for use Limitations Sponsor * * * * * * * (iii) 36.3 to 113.5 Bacitracin methylenedisalicylate, 50 Replacement chickens: For development of active immunity to coccidiosis; and as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin Feed continuously as the sole ration as in the subtable in item (i). Grower ration not to be fed to birds over 14 weeks of age. Bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter 054771 058198 (iv) 36.3 to 113.5 Bacitracin methylenedisalicylate, 100 to 200 Replacement chickens: For development of active immunity to coccidiosis; and as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin Feed continuously as sole ration as in the subtable in item (i). To control necrotic enteritis, start medication at first clinical signs of disease; vary bacitracin dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 g/ton). Bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter 054771 058198 * * * * * * * (vii) 113.5 Bacitracin methylenedisalicylate, 50 Broiler chickens: For prevention and control of coccidiosis; and as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin Feed continuously as the sole ration. Bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter 054771 058198 (viii) 113.5 Bacitracin methylenedisalicylate, 100 to 200 Broiler chickens: For prevention and control of coccidiosis; and as an aid in the control of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin Feed continuously as sole ration. To control necrotic enteritis, start medication at first clinical signs of disease; vary bacitracin dosage based on the severity of infection; administer continuously for 5 to 7 days or as long as clinical signs persist, then reduce bacitracin to prevention level (50 g/ton). Bacitracin methylenedisalicylate as provided by No. 054771 in § 510.600(c) of this chapter 054771 058198 * * * * * * * (2) Turkeys — Start Printed Page 17949
Zoalene in grams/ton Combination in grams/ton Indications for use Limitations Sponsor (i) 113.5 to 170.3 Growing turkeys: For prevention and control of coccidiosis Feed continuously as sole ration. For turkeys grown for meat purposes only. Not to be fed to laying birds 054771 058198 (ii) 113.5 to 170.3 Bacitracin methylenedisalicylate, 4 to 50 Growing turkeys: For prevention and control of coccidiosis; and for increased rate of weight gain and improved feed efficiency Feed continuously as sole ration until 14 to 16 weeks of age. For turkeys grown for meat purposes only. Not to be fed to laying birds 054771 058198 * * * * *Dated: March 21, 2022.
Andi Lipstein Fristedt,
Deputy Commissioner for Policy, Legislation, and International Affairs, U.S. Food and Drug Administration.
[FR Doc. 2022-06395 Filed 3-28-22; 8:45 am]
BILLING CODE 4164-01-P
Document Information
- Effective Date:
- 3/29/2022
- Published:
- 03/29/2022
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final rule; technical amendments.
- Document Number:
- 2022-06395
- Dates:
- This rule is effective March 29, 2022.
- Pages:
- 17942-17949 (8 pages)
- Docket Numbers:
- Docket No. FDA-2021-N-0002
- Topics:
- Administrative practice and procedure, Animal drugs, Animal feeds, Confidential business information, Dairy products, Foods, Labeling, Meat and meat products, Reporting and recordkeeping requirements
- PDF File:
- 2022-06395.pdf
- Supporting Documents:
- » New Animal Drugs; Withdrawal of Approval of New Animal Drug Application
- » FOI Summary sN 141-063 approved August 19 2021
- » FOI Summary oA 200-708 approved August 2 2021
- » FOI Summary sN 140-269 approved May 25 2021 RE New Animal Drugs; Approval of New Animal Drug Applications; Changes of Sponsor Address
- » FOI Summary oN 141-543 approved June 1 2021 RE New Animal Drugs; Approval of New Animal Drug Applications; Changes of Sponsor Address
- » FOI Summary oA 200-702 approved April 23 2021 RE New Animal Drugs; Approval of New Animal Drug Applications; Changes of Sponsor Address
- » FOI Summary sN 141-452 approved May 18 2021 RE New Animal Drugs; Approval of New Animal Drug Applications; Changes of Sponsor Address
- » FOI Summary sN 128-620 approved June 14 2021 RE New Animal Drugs; Approval of New Animal Drug Applications; Changes of Sponsor Address
- » FOI Summary oA 200-700 approved June 10 2021 RE New Animal Drugs; Approval of New Animal Drug Applications; Changes of Sponsor Address
- » FOI Summary oA 200-697 approved April 5 2021 RE New Animal Drugs; Approval of New Animal Drug Applications; Changes of Sponsor Address
- CFR: (26)
- 21 CFR 510.600
- 21 CFR 516.498
- 21 CFR 520.2090
- 21 CFR 520.2455
- 21 CFR 522.246
- More ...